Concepedia

Author

Ronald L. Dubowy

SUNY Upstate Medical University

Also Known As

Dubowy, R L, R Dubowy, R L Dubowy, R. Dubowy, R. L. Dubowy, Ronald Dubowy, Ronald L Dubowy, Ronald L. Dubowy

88

Publications

3.3K

Citations

29

H-Index

82

Concepts

All Affiliations

SUNY Upstate Medical UniversitySyracuse UniversityGilead Sciences (United States)Memorial Sloan Kettering Cancer CenterSarah Cannon
RL

About

Ronald L. Dubowy is an author at SUNY Upstate Medical University specializing in medicine, oncology, and cancer research.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

16

21

1.3K

2

Health Sciences

9

9

996

3

Education

1

1

16

4

Natural Sciences

1

1

38

5

Allergy

1

1

12

Ronald L. Dubowy

×

52

Publications

3.2K

Citations

28

H-Index

YearCitations

SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor–Naïve Patients With Myelofibrosis

Ruben A. Mesa, Jean‐Jacques Kiladjian, John Catalano,

Journal of Clinical Oncology

2017

345

Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498 [see comments]

Yaddanapudi Ravindranath, Esteban Abella, J. Krischer,

Blood

1992

257

A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia

Susan O’Brien, Nicole Lamanna, Thomas J. Kipps,

Blood

2015

239

Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study

Alison R. Sehgal, Daanish Hoda, Peter A. Riedell,

The Lancet Oncology

2022

217

Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial

Jeffrey A. Jones, Tadeusz Robak, Jennifer R. Brown,

The Lancet Haematology

2017

198

Intensive chemotherapy followed by consolidative myeloablative chemotherapy with autologous hematopoietic cell rescue (AuHCR) in young children with newly diagnosed supratentorial primitive neuroectodermal tumors (sPNETs): Report of the Head Start I and II experience

Jason Fangusaro, Jonathan L. Finlay, Richard Sposto,

Pediatric Blood & Cancer

2007

139

Intensive Therapy With Growth Factor Support for Patients With Ewing Tumor Metastatic at Diagnosis: Pediatric Oncology Group/Children's Cancer Group Phase II Study 9457—A Report From the Children's Oncology Group

Mark L. Bernstein, Meenakshi Devidas, Dominique Lafreniere,

Journal of Clinical Oncology

2005

137

A comparative study of the long term psychosocial functioning of childhood acute lymphoblastic leukemia survivors treated by intrathecal methotrexate with or without cranial radiation.

James M. Hill, Alice B. Kornblith, Dana Jones,

PubMed

1998

129

A comparative study of the long term psychosocial functioning of childhood acute lymphoblastic leukemia survivors treated by intrathecal methotrexate with or without cranial radiation

James M. Hill, Alice B. Kornblith, Dana Jones,

Cancer

1998

115

Outcome for young children newly diagnosed with ependymoma, treated with intensive induction chemotherapy followed by myeloablative chemotherapy and autologous stem cell rescue

Stergios Zacharoulis, Adam Levy, Sharon L. Gardner,

Pediatric Blood & Cancer

2006

112

Page 1